January 8, 2021
Tagrisso as Adjuvant Therapy for NSCLC Approved
Tagrisso as adjuvant therapy for non-small cell lung cancer approved by the FDA for patients who have had tumor resection.
CURE®
Research News
Latest Advances in Lung Cancer Research
Explore our curated selection of the latest breakthroughs in lung cancer research.
-
-
January 8, 2021
Trailblazer KRAS treatment filed with FDA
Amgen has filed its trailblazer KRAS inhibiting drug treatment with the FDA for a group of lung cancer patients with an aggressive form of the disease.
PharmaPhorum
Get the latest lung cancer research news directly in your inbox.
Learn more about:
- the latest science in lung cancer
- stories about living with lung cancer
- how LCFA is working to fund more lung cancer research grants
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.